Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients

Pediatric Drugs

Volumn 4, Issue 7, 2002, Pages 469-484

  Kraus, Donna M ^a   Pai, Manjunath P ^a   Rodvold, Keith A ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; CEFTAZIDIME; CEFTRIAXONE; GENTAMICIN; IMIPENEM; NETILMICIN; TOBRAMYCIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; BACTEREMIA; BACTERICIDAL ACTIVITY; CHILD; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG TOLERABILITY; FEBRILE NEUTROPENIA; GRAM NEGATIVE INFECTION; HUMAN; INFANT; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NEPHROTOXICITY; NEWBORN; OTOTOXICITY; POSTANTIBIOTIC EFFECT; PRIORITY JOURNAL; REVIEW; ARTICLE; DELAYED RELEASE FORMULATION; ECONOMICS; METHODOLOGY; NEUTROPENIA; PEDIATRICS; PRESCHOOL CHILD; STATISTICS;

AMINOGLYCOSIDES; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; CYSTIC FIBROSIS; DELAYED-ACTION PREPARATIONS; HUMANS; INFANT; INFANT, NEWBORN; NEUTROPENIA; PEDIATRICS;

EID: 0035985755     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204070-00005     Document Type: Review

References (79)

1. National survey of extended-interval aminoglycoside dosing
2. Once daily versus multiple-daily dosing of aminoglycosides
3. Daily dosage of aminoglycosides
4. Once-daily dosing of aminoglycosides: Review and recommendations for clinical practice
5. The pharmacodynamics of aminoglyclosides
6. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin
7. Influencc of dosage schedule on renal cortical accumulation of amikacin and tobramycin in man
8. Once daily aminoglycoside therapy: Is it less toxic than multiple daily doses and how should it be monitored
9. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides
10. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides
11. Single daily dosing of aminoglycosides in immunocompromised adults: A systematic review
12. Mega-analysis or meta-analysis: An examination of meta-analysis with an emphasis on once-daily aminoglycoside comparative trials
13. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis
14. Once-daily aminoglycoside dosing in immunocompetent adults: A meta-analysis
15. A meta analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses
16. Single or multiple daily doses of aminoglycosides: A meta-analysis
17. National survey of once daily dosing of aminoglycoside antibiotics
18. Once daily aminoglycoside: Impact on requests and costs for therapeutic drug monitoring
19. Once-daily aminoglycoside administration in gram-negative sepsis: Economic and practical aspects
20. Some international approaches to aminoglycoside monitoring in the extended dosing interval era
21. Single daily doses of aminoglycosides
22. An emotional-based medicine approach to monitoring once-daily aminoglycosides
23. Kinetics of gentamicin uptake and release in the rat: Comparison of inner ear tissues and fluid with other organs
24. Comparative uptake of gentamicin, netilmicin, and amikacin in the guinea pig cochlea and vestibule
25. Pharmacodynamics of amikacin in vitro, and in mouse thigh and lung infections
26. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model
27. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration
28. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria
29. Post antibiotic effects in experimental infection models: Relationship to in-vitro phenomena and to treatment of infections in man
30. Factors affecting duration of in-vivo postantibiotic effect for aminoglycosides against gram-negative bacilli
31. In vivo postantibiotic effect in a thigh infection in neutropenic mice
32. Single, large, daily dosing versus intermittent dosing of tobramycin for treating experimental pseudomonas pneumonia
33. Adaptive resistance to aminoglycoside antibiotics from first exposure down-regulation
34. First-exposure adaptive resistance to aminoglycoside antibiotics in vivo with meaning for optimal clinical use
35. Adaptive resistance to aminoglycoside antibiotics in Pseudomonas aeruginosa
36. Nephrotoxicity, high frequency ototoxicity, efficacy and serum kinetics of once versus thrice daily dosing of netilmicin in patients with serious infections
37. Aminoglycoside adaptive resistance: Important for effective dosage regimens
38. Aminoglycoside nephrotoxicity
39. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats
40. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity
41. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside
42. Ototoxicity: Clinical considerations and comparative information
43. The aminoglycosides
44. Gentamicin-induced bilateral vestibular hypofunction
45. Pharmacokinetics of once-daily gentamicin dosing in pediatric patients
46. Pharmacokinetics and antibacterial activity of daily gentamicin
47. Pharmacokinetics of once-daily dosing of gentamicin in neonates
48. Once daily gentamicin dosing in neonates
49. Once daily gentamicin in neonates of all gestations
50. Once daily gentamicin dosing in newborn infants
51. Once- versus twice-daily gentamicin dosing in neonates ≥34 weeks' gestation: Cost-effectiveness analyses
52. Once daily dosing of netilmicin in neonatal and pediatric intensive care
53. Once-a-day administration of amikacin in neonates: Assessment of nephrotoxicity and ototoxicity
54. Adaptation in neonatology of the once-daily concept of aminoglycoside administration: Evaluation of a dosing chart for amikacin in an intensive care unit
55. Once versus twice daily amikacin in neonates: Prospective study on toxicity
56. Gentamicin once-daily versus thrice-daily in children
57. Single daily dose amikacin in paediatric patients with severe gram-negative infections
58. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe gram-negative infections
59. The pharmacokinetics of amikacin in critically ill adult and paediatric patients: Comparison of once- versus twice-daily dosing regimens
60. A prospective randomized study comparing once- versus twice-daily amikacin dosing in critically ill adult and paediatric patients
61. A comparison of two amikacin dosing regimens in paediatric surgical patients
62. Once daily ceftriaxone and gentamicin for the treatment of febrile neutropenia
63. Serum concentrations and safety of single daily dosing of amikacin in children undergoing bone marrow transplantation
64. Once daily antibiotic regimen in paediatric oncology
65. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia
66. Once daily ceftriaxone plus amikacin vs three times daily ceftazidime plus amikacin for treatment of febrile neutropenic children with cancer
67. Pharmacokinetic analysis of amikacin twice and single daily dosage in immunocompromised pediatric patients
68. The pharmacokinetics and toxicity of once-daily tobramycin therapy in children with cystic fibrosis
69. Efficacy, tolerance, and pharmacokinetics of once daily tobramycin for pseudomonas exacerbations in cystic fibrosis
70. Pharmacokinetics and bronchial diffusion of single daily dose amikacin in cystic fibrosis patients
71. Tolerance, pharmacokinetics and efficacy of once daily amikacin for treatment of Pseudomonas aeruginosa pulmonary exacerbations in cystic fibrosis patients
72. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine
73. An extended interval dosing method for gentamicin in neonates
74. Use of higher dose extended interval aminoglycosides in a neonatal intensive care unit
75. Comparison of 5 milligrams of netilmicin per kilogram of body weight once daily versus 2 milligrams per kilogram thrice daily for treatment of gram-negative pyelonephritis in children
76. Randomized, controlled trial comparing once daily and three times daily gentamicin in children with urinary tract infections
77. Experience with a once-daily aminoglycoside program administered in 2.184 adult patients
78. Cost-effectiveness of ceftriaxone and amikacin as single daily dose for the empirical management of febrile granulocytopenic children with cancer